Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q4 FY25
Investor Presentation
Q4 FY24
Investor Presentation
Q4 FY24
Investor Presentation
Q1 FY24
Investor Presentation
Q4 FY22
Bearish
3
Neutral
7
Bullish
4
Bearish
3
Neutral
7
Bullish
36
Bearish
0
Neutral
0
Bullish
32
Discovery themes featuring this stock
Kwality Pharmaceuticals is an India-based finished dosage and complex injectables manufacturer and CDMO focusing on injectables, biologics, oncology formulations and beta-lactams; it sells primarily by out-licensing and supply across 70+ countries and operates multiple EU/PICs/WHO-accredited manufacturing units with an active R&D centre recognised by DSIR.
Export-led, asset-light model: about 90% of revenue comes from out-licensing and supply while CDMO contributes ~10%, enabling rapid international expansion with limited front-end commercial risk and a filing cadence that rose from 75 (FY23) to 200 (FY26). This strategic mix drives stable export revenues but lengthens receivable cycles.
Financial momentum is visible: FY25 revenue at INR 370 crore and PAT INR 40 crore, with 22% CAGR over FY23–25 and strong Q3FY26 performance (Q3 revenue up 46% YoY; PAT up 88% YoY). Management targets 35% growth in FY26 and aims for INR 650+ crore by FY27 with margin expansion to 25% EBITDA.
Regulatory and capability moat: 4 of 5 manufacturing units cleared EU/PICs GMP and the company lists multiple international accreditations (ANVISA, INVIMA, SFDA etc.), supporting entry into regulated markets and underpinning its ambition to commercialize biologics and biosimilars for higher-margin geographies.
Operational improvements and balance sheet health provide execution cushion: working capital days declined materially (297 to 208), ROCE improved to 22% in FY25, and Net Debt/Equity moderated to 0.38, giving Kwality Pharmaceuticals headroom to fund ongoing capacity build and R&D without aggressive leverage.
Pharmaceuticals & Biotechnology
Pharmaceuticals
2,881 Cr
Low Risk
42.4
36.7
0.6
8.7
2,889.00
828.80
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
53.88 | 2,947 Cr | 39.55 | 2.36 | 0.37 | 5.96 | 7.58 | 4.94 | ||
184.15 | 2,886 Cr | 29.12 | 0.43 | 0.00 | 1.46 | 2.66 | 0.82 | ||
2776.90 | 2,881 Cr | 42.40 | 8.71 | 0.00 | 20.31 | 21.46 | 11.37 | ||
442.00 | 2,699 Cr | — | 3.23 | 0.00 | -2.93 | -2.42 | -0.57 | ||
218.35 | 2,678 Cr | 73.88 | 2.23 | 0.28 | 3.03 | 3.56 | -2.06 | ||
2315.60 | 2,413 Cr | 52.93 | 9.85 | 0.00 | 16.95 | 17.46 | 9.33 | ||
539.95 | 2,377 Cr | 166.58 | 4.84 | 0.00 | 2.91 | 2.79 | — | ||
| Median: 7 Co. | — | 442.00 | 2,699 Cr | 47.66 | 3.23 | 0.00 | 3.03 | 3.56 | 2.88 |
Product/Operations Update
Kwality Pharmaceuticals Ltd received CDSCO permission to manufacture pilot-scale preclinical batches of Pembrolizumab, advancing the candidate to the preclinical stage toward a future generic launch after patent expiry.
Product/Operations Update
Kwality Pharmaceuticals received CDSCO permission to manufacture pilot-scale preclinical batches of Pembroluzimab, advancing the product to pre-clinical stage and positioning KPL for potential generic launch post-patent expiry.
Kwality Pharmaceuticals Ltd (KPL) is currently trading at 2,776.90 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Kwality Pharmaceuticals is an India-based finished dosage and complex injectables manufacturer and CDMO focusing on injectables, biologics, oncology formulations and beta-lactams; it sells primarily by out-licensing and supply across 70+ countries and operates multiple EU/PICs/WHO-accredited manufacturing units with an active R&D centre recognised by DSIR. Export-led, asset-light model: about 90% of revenue comes from out-licensing and supply while CDMO contributes ~10%, enabling rapid international expansion with limited front-end commercial risk and a filing cadence that rose from 75 (FY23) to 200 (FY26). This strategic mix drives stable export revenues but lengthens receivable cycles. Financial momentum is visible: FY25 revenue at INR 370 crore and PAT INR 40 crore, with 22% CAGR over FY23–25 and strong Q3FY26 performance (Q3 revenue up 46% YoY; PAT up 88% YoY). Management targets 35% growth in FY26 and aims for INR 650+ crore by FY27 with margin expansion to 25% EBITDA. Regulatory and capability moat: 4 of 5 manufacturing units cleared EU/PICs GMP and the company lists multiple international accreditations (ANVISA, INVIMA, SFDA etc.), supporting entry into regulated markets and underpinning its ambition to commercialize biologics and biosimilars for higher-margin geographies. Operational improvements and balance sheet health provide execution cushion: working capital days declined materially (297 to 208), ROCE improved to 22% in FY25, and Net Debt/Equity moderated to 0.38, giving Kwality Pharmaceuticals headroom to fund ongoing capacity build and R&D without aggressive leverage.
Over the past 52 weeks, Kwality Pharmaceuticals Ltd has traded between a low of ₹828.80 and a high of ₹2,889.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Kwality Pharmaceuticals Ltd has a market capitalization of approximately 2,881.37. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Kwality Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 42.40 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 2,881.37 Cr, Kwality Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Kwality Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Kwality Pharmaceuticals Ltd is 42.40. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
